Lupin is currently trading at Rs. 467.60, up by 1.50 points or 0.32% from its previous closing of Rs. 466.10 on the BSE.
The scrip opened at Rs. 461.25 and has touched a high and low of Rs. 473.50 and Rs. 412.15 respectively. So far 22606 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 517.00 on 02-Dec-2010 and a 52 week low of Rs. 363.00 on 25-Feb-2011.
Last one week high and low of the scrip stood at Rs. 484.00 and Rs. 412.15 respectively. The current market cap of the company is Rs. 20815.40 crore.
The promoters holding in the company stood at 46.94% while Institutions and Non-Institutions held 43.33% and 9.72% respectively.
Pharma Major, Lupin’s US subsidiary - Lupin Pharmaceuticals, Inc. has received final approval for its Minocycline hydrochloride extended release tablets 45mg, 55mg, 90mg and 135mg strengths from the United States Food and Drugs Administration (USFDA) for the company’s abbreviated new drug application (ANDA) to market a generic version of Medicis Oharmaceutical Corporation’s Solodyn extended-release tablets.
Solodyn is an oral antibiotic approved to treat only the red, pus-filled pimples of moderate to serve acne in patients 12 years of age and older. Medicis’ Solodyn extended-release tablets had sales of $750 million September, 2011.
Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. Lupin has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.55 |
Dr. Reddys Lab | 1356.05 |
Cipla | 1464.90 |
Lupin | 2154.00 |
Zydus Lifesciences | 972.05 |
View more.. |